ストックスクリーナーアプリを入手
3.18
12.37%
0.35
プレマーケット:
2.97
-0.21
-6.60%
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus - TechStock²
Crude Oil Down 4%; PayPal Shares Fall After Q1 Results - Benzinga
CLRB Stock Surges 28.6% on $140M Financing and Positive Trial Data - Meyka
Cellectar Biosciences announces up to $140M financing deal; shares surge - MSN
Dow Jumps Over 300 Points; Tyson Foods Posts Upbeat Earnings - Benzinga
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia - Investing News Network
Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia - Yahoo Finance
CLRB Stock Pops As New Cancer Trial Sparks Trading Interest - StocksToTrade
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses - Benzinga
Cellectar Biosciences raises up to $140 million in financing By Investing.com - Investing.com South Africa
CLRB Stock Jumps As New Breast Cancer Trial Begins - timothysykes.com
Cellectar reports 12-month data for WM treatment trial - Investing.com
Cellectar reports 12-month data for WM treatment trial By Investing.com - Investing.com Canada
Cancer drug posts 17.8-month responses after four 30-minute infusions - Stock Titan
Cellectar Biosciences Inc. (CLRB) has successfully completed a financing round, led by Nantahala Capital Management, LLC. - Bitget
Cellectar Biosciences raises up to $140 million in financing - Investing.com
Cellectar Biosciences stock soars 130% on $140M financing By Investing.com - Investing.com Australia
Cellectar Biosciences Reports Positive 12-Month Follow-Up - GlobeNewswire
Cellectar Biosciences stock soars 130% on $140M financing - Investing.com
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million - The Manila Times
Cellectar lines up $140M to fund cancer drug study and FDA filing - Stock Titan
MSN - MSN
Cellectar Biosciences (CLRB) price target decreased by 59.62% to 14.28 - MSN
MSN Money - MSN
Cellectar Biosciences (NASDAQ: CLRB) details governance, ownership and financings in 10-K/A - Stock Titan
CLRB Price Today: Cellectar Biosciences INC NEW Stock Price, Quote & Chart | MEXC - MEXC Exchange
CLRB (Cellectar Biosciences Inc.) reports narrower than expected Q4 2025 loss, yet shares drop nearly 3 percent.High Interest Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Cellectar to present WM treatment data at oncology meeting By Investing.com - Investing.com Australia
Cellectar to present WM treatment data at oncology meeting - Investing.com
Cellectar Biosciences, Inc. Announces Acceptance of Abstract for Presentation on Iopofosine I-131 at ASCO Annual Meeting - Quiver Quantitative
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 - marketscreener.com
Cellectar takes cancer-drug data to ASCO for patients with no approved therapy - Stock Titan
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences (CLRB) Begins Phase 1b Trial for Triple Ne - GuruFocus
Cellectar enrolls first patient in phase 1b cancer trial By Investing.com - Investing.com South Africa
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Triple Negative Breast Cancer - National Today
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Refractory Triple Negative Breast Cancer - National Today
Cellectar enrolls first patient in phase 1b cancer trial - Investing.com
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) - The Manila Times
First patient joins Cellectar study for hard-to-treat breast cancer - Stock Titan
Cellectar Initiates Phase 1b Trial for Triple Negative Breast Cancer - Intellectia AI
Aug Summary: How volatile is Cellectar Biosciences Inc stock2026 Spike Watch & Daily Entry Point Trade Alerts - baoquankhu1.vn
Aug Mood: Can Cellectar Biosciences Inc weather a recession2026 PostEarnings & Entry Point Strategy Guides - baoquankhu1.vn
CEO Moves: Is Cellectar Biosciences Inc a top pick in the sectorIPO Watch & Weekly Top Performers Watchlists - baoquankhu1.vn
Growth Value: Will Cellectar Biosciences Inc stock benefit from M AQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Trading Action: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Buybacks Report: How does Cellectar Biosciences Inc compare to its peersQuarterly Portfolio Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
Is Cellectar (CLRB) Stock Cheap at Current Price | Price at $2.68, Up 5.10%Asset Allocation - Xã Thanh Hà
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Aug Technicals: Will Cellectar Biosciences Inc outperform during market ralliesOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Smart Money: Is Cellectar Biosciences Inc a top pick in the sectorQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
VIX Spike: Can Cellectar Biosciences Inc weather a recessionTrade Risk Assessment & Community Verified Trade Alerts - baoquankhu1.vn
What drives Cellectar Biosciences Incs stock price2026 Risk Factors & Weekly High Potential Stock Alerts - baoquankhu1.vn
ETF Watch: Will WASH benefit from geopolitical trendsShare Buyback & Stepwise Trade Signal Implementation - baoquankhu1.vn
Big Money Moves: How cyclical is Cellectar Biosciences Incs revenue streamTrade Entry Report & Smart Swing Trading Alerts - baoquankhu1.vn
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):